News

To accelerate study of the MicroStent microvascular device and other new technologies designed to prevent amputation, MMS has assembled six world leaders in treating peripheral artery disease and critical limb ischemia.

WILMINGTON, Massachusetts, April 26, 2018 — Micro Medical Solutions (MMS), an innovator in the field of microvascular interventions that improve clinical outcomes and quality of life, announced today that it has completed building a Scientific Advisory Board that includes six international leaders in treatment of peripheral artery disease (PAD) and critical limb ischemia (CLI). Formation of this dedicated group of physicians positions MMS to plan and carry out clinical trials and explore new treatment advances.

“We are excited to bring this group of highly esteemed physicians on to our Advisory Board,” said MMS Chief Medical Officer, Dr. Jihad Mustapha. “PAD and CLI affect millions. Nearly 25% of people with CLI will undergo limb amputation,1 and that number continues to rise.2 Just like each physician on our board who battles PAD and CLI, MMS has a mission to reduce preventable amputations. The Scientific Advisory Board will guide current clinical studies for MicroStent and other technologies in development, helping MMS to develop new treatments that save limbs and improve lives.”

“The formation of the MMS Scientific Advisory Board represents an integral step in our clinical progress and strategic positioning for the future,” noted Medical Solutions CEO Gregory Sullivan. “We can now draw on the clinical experience and vision of six world leaders in PAD and CLI treatment at a critical time, as MicroStent enters a clinical study in the U.S. and completes firstin- man cases abroad. With the board’s guidance and new additions to our leadership team in Clinical Affairs, the company continues to build momentum toward our goal of reducing amputations worldwide.”

The following physicians now sit on the MMS Scientific Advisory Board:

About Micro Medical Solutions

Micro Medical Solutions is on a mission to provide solutions to some of the most pressing unmet needs in microvascular intervention by helping to significantly reduce the rate of amputations, improve clinical outcomes and patient quality of life, and minimize the financial and human costs associated with the treatment of peripheral artery disease and critical limb ischemia. For more about Micro Medical Solutions, visit www.micromedicalsolutions.net.

About CLI

Peripheral artery disease (PAD) and critical limb ischemia (CLI) affected 215 million people worldwide in 2015, predicted to be 230 million by 2020.1 CLI currently afflicts 2.8 to 3.5 million of those with PAD and is projected to rise to 4.5 to 5.6 million.2 Rates of amputations in the general population with PAD are declining, but amputations in CLI continue to escalate. It has been estimated that 25% of CLI patients will undergo major amputation. Prognosis with respect to limb preservation in CLI patients is poor, particularly in no-option CLI patients, where six-month major amputation rates have been reported to be as high as 50%.3 If something doesn’t change, the number of amputations due to CLI could exceed one million by 2030.